Anticoagulant Rodenticide Toxicity to Non-Target Wildlife Under Controlled Exposure Conditions Barnett A

Total Page:16

File Type:pdf, Size:1020Kb

Anticoagulant Rodenticide Toxicity to Non-Target Wildlife Under Controlled Exposure Conditions Barnett A University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln USDA National Wildlife Research Center - Staff U.S. Department of Agriculture: Animal and Plant Publications Health Inspection Service 2018 Anticoagulant Rodenticide Toxicity to Non-target Wildlife Under Controlled Exposure Conditions Barnett A. Rattner U.S. Geological Survey, [email protected] F. Nicholas Mastrota USEPA Follow this and additional works at: https://digitalcommons.unl.edu/icwdm_usdanwrc Part of the Life Sciences Commons Rattner, Barnett A. and Mastrota, F. Nicholas, "Anticoagulant Rodenticide Toxicity to Non-target Wildlife Under Controlled Exposure Conditions" (2018). USDA National Wildlife Research Center - Staff Publications. 2103. https://digitalcommons.unl.edu/icwdm_usdanwrc/2103 This Article is brought to you for free and open access by the U.S. Department of Agriculture: Animal and Plant Health Inspection Service at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in USDA National Wildlife Research Center - Staff ubP lications by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. Chapter 3 Anticoagulant Rodenticide Toxicity to Non- target Wildlife Under Controlled Exposure Conditions Barnett A. Rattner and F. Nicholas Mastrota 1 Introduction Our knowledge of the toxicity of anticoagulant rodenticides (ARs) can be traced to investigations of Karl Paul Link and colleagues on “bleeding disease” in cattle, the eventual isolation of dicoumarol from moldy sweet clover, synthesis of this causative agent, and its application as a therapeutic anticoagulant in clinical medicine in 1941 (Link 1959). The notion of a coumarin-based rodenticide as a better “mouse-trap” occurred to Link in 1945 while reviewing laboratory chemical and bioassay data. By 1948, the highly potent compound number 42, warfarin, was promoted as a rodenti- cide (Link 1959; Last 2002). Through laboratory studies and clinical use of warfarin (Coumadin), a detailed understanding of the mechanism of action and toxicity of warfarin and related ARs (Fig. 3.1) unfolded in the decades that followed. Our understanding of AR toxicity has been principally derived from an array of biochemical through whole animal studies. Structure-activity relationship models indicate that AR potency (i.e., toxicity in rodents) is related to the length and hydro- phobicity of the side chain in the vicinity of carbon 13 (Fig. 3.2), with the most active compounds having greater volume and bulky lipophilic groups in this activity domain (Thijssen 1995; Domella et al. 1999). At the molecular level, both coumadin- and indandione-based ARs inactivate vitamin K epoxide reductase (VKOR), a membrane protein present in the endoplasmic reticulum of liver and other tissues. Catalytic activity of VKOR is required for the reduction of vitamin K epoxide and vitamin K to form vitamin K hydroquinone (Fig. 3.3). This biologically-active B.A. Rattner (*) U.S. Geological Survey, Patuxent Wildlife Research Center, BARC East-Building 308, 10300 Baltimore Avenue, Beltsville, MD 20705, USA e-mail: [email protected] F.N. Mastrota U.S. Environmental Protection Agency, Office of Chemical Safety and Pollution Prevention, Washington, DC 20460, USA © Springer International Publishing AG 2018 45 N.W. van den Brink et al. (eds.), Anticoagulant Rodenticides and Wildlife, Emerging Topics in Ecotoxicology 5, DOI 10.1007/978-3-319-64377-9_3 46 B.A. Rattner and F.N. Mastrota First-generation hydroxycoumarins Warfarin Coumachlor 81-81-2 81-82-3 Coumafuryl Coumatetralyl 117-52-2 5836-29-3 Intermediate-generation indandiones Chlorophacinone Diphacinone Pindone 3691-35-8 82-66-6 83-26-1 Fig. 3.1 Class, compound, Chemical Abstracts Service Number and structure of 12 anticoagulant rodenticides (From: https://www.ncbi.nlm.nih.gov/pccompound) hydroquinone is required for γ-glutamyl carboxylation of clotting factors. Inhibition of VKOR by ARs limits the formation of vitamin K hydroquinone resulting in under-carboxylation of clotting factors II, VII, IX and X (Furie et al. 1999) that do not assemble on cell surfaces to form a clot. It is believed that ARs bind tightly to the proposed warfarin-binding site of VKOR at tyrosine residue 135 in close proximity to the active site (cysteines 132 and 135) of this 163 amino acid enzyme (Tie and Stafford 2008). Notably, some point mutations can impede AR binding and thus confer resistance in target pest species (Boyle 1960; Pelz et al. 2005). Once the fully-functional clotting factors are cleared from the blood, the des-γ carboxyl dysfunctional clotting factors no longer support hemostasis. Hemorrhage may ensue spontaneously or can be triggered by traumatic events. Coagulopathy may be accompanied by anemia, hypovolemic shock, altered tissue perfusion, organ 3 Anticoagulant Rodenticide Toxicity to Non-target Wildlife Under Controlled… 47 Second-generation hydroxycoumarins Brodifacoum Bromadiolone Difenacoum 56073-10-0 28772-56-7 56073-07-5 Difethialone Flocoumafen 104653-34-1 90035-08-8 Fig. 3.1 (continued) dysfunction, and necrosis. Overt signs of intoxication include bruising, bleeding, blood in droppings and urine, pallor, and other signs not specific to coagulopathy (e.g., asthenia, ataraxia, labored breathing, immobility). The proximate cause of death may seemingly be unrelated to AR poisoning, but in fact ultimately triggered by AR-residues and coagulopathy. In addition to impaired blood clotting, some ARs have been shown to increase membrane permeability, affect other vitamin K-dependent proteins, growth factors, and signal transduction (reviewed in Rattner et al. 2014a). Notably, large doses of indandiones can cause toxicity and result in death independent of coagulopathy (Kabat et al. 1944), probably by impairing cellular energy generation through the uncoupling of oxidative phosphorylation Fig. 3.2 Structure of the first-generation anticoagulant rodenticides warfarin and diphacinone, and the second- generation anticoagulant rodenticide brodifacoum, illustrating side chains (red) of the activity domain (*) in vicinity of carbon 13 (Modified with permission from Rattner et al. 2014a, Copyright 2015 American Chemical Society) (Color figure online) Fig. 3.3 Vitamin K cycle illustrating anticoagulant rodenticide (AR) sensitive vitamin K epoxide reductase (VKOR) reactions and a warfarin-insensitive VKOR that reduces vitamin K to the biologically- active vitamin K hydroquinone. Without adequate vitamin K hydroquinone, γ-glutamyl carboxylase (critical reaction circled in green) lacks substrate to adequately carboxyl- ate clotting factors II, VII, IX and X (Reprinted with permission from Rattner et al. 2014a, Copyright 2015 American Chemical Society) 3 Anticoagulant Rodenticide Toxicity to Non-target Wildlife Under Controlled… 49 (van den Berg and Nauta 1975). Numerous controlled exposure studies have docu- mented in vitro biochemical effects, and in vivo physiological, pharmacological and whole organism responses in domesticated species and to a lesser degree captive wildlife (reviewed in IPCS 1995; Joermann 1998; Rattner et al. 2014a), and much is known from clinical use and accidental poisoning incidents in humans (Watt et al. 2005). Recently, a proposed adverse outcome pathway, identifying the molecular initiating/anchoring event, and established and plausible linkages associated with toxicity through individual and even population levels, has been developed for non- target predatory birds and mammals (Fig. 3.4) (Rattner et al. 2014a) The use of vertebrate pesticides, and specifically ARs, requires detailed toxico- logical knowledge and regulatory evaluation to ensure a compound does not pose an unacceptable risk to non-target biota and the environment (Eason et al. 2010). The review and approval process takes into account economic, social and environmental costs and benefits (Eason et al. 2010). An integral component of this process is the generation of toxicity data for non-target wildlife. These data are used to examine the potential hazard and risk associated with direct bait ingestion and consumption of AR-exposed prey by non-target species. For purposes of AR registration, much of these data are generated using standardized toxicity testing methods. However, additional research on AR absorption, distribution, metabolism, pharmacokinetics and underlying mechanism of action is often undertaken to more fully evaluate and explain interspecific differences in toxicity. The generation of these data usually entails in vivo testing in species maintained in captivity using various exposure scenarios. This chapter will principally focus on data generated from such studies in terrestrial wildlife (mammals, birds and reptiles) or domesticated surrogate species used to predict effects in non-target wildlife. 1.1 Standardized Tests, Their Limitations and Implications As terrestrial wildlife may be exposed by direct consumption of AR-containing bait and/or by predation or scavenging on exposed or poisoned rodents, standard- ized tests have focused on the dietary route of exposure. Notably, exposure path- ways have yet to be clearly elucidated for aquatic species. Standardized testing protocols allow regulators to compare the toxicities of various chemicals to ter- restrial wildlife and examine the range of species sensitivities to a particular chemical. In the wildlife- pesticide regulatory arena, the most commonly used endpoint for toxicity is mortality because of its definitive nature. The two most commonly conducted standardized
Recommended publications
  • “Baits and Baiting Strategies for Multi-Species Pest Control and Feral
    Baits and baiting strategies for multi-species pest control and feral cats SCIENCE FOR CONSERVATION: 40 D.R. Morgan, J. Innes, C. Ryan, L. Meikle Published by Department of Conservation P.O. Box 10-420 Wellington, New Zealand 1 Science for Conservation presents the results of investigations contracted to science providers outside the Department of Conservation. Reports are subject to peer review within the Department and, in some instances, to a review from outside both the Department and the science providers. November 1996, Department of Conservation ISSN 1173-2946 ISBN 0-478-01855-X This publication originated from work done under Department of Conservation contract 1748 carried out by D.R. Morgan, J. Innes and C. Ryan, Manaaki Whenua – Landcare Research, P.O. Box 69, Lincoln; and contract 617, carried out by D.R. Morgan and L. Meikle, Manaaki Whenua – Landcare Research, P.O. box 31-011, Christchurch. It was approved for publication by the Director, Science and Research Division, Department of Conservation, Wellington. Cataloguing-in-Publication data Baits and baiting strategies for multi-species pest control and feral cats / D.R. Morgan ... {et al.} Wellington, N.Z. : Dept. of Conservation, 1996. 1 v. ; 30 cm. (Science for conservation, 1173-2946 ; 40.) Includes bibliographical references. ISBN 047801855X 1. Pests- -Control- -New Zealand. I. Morgan, D.R. (David Rowland), 1950- II. Series: Science for conservation (Wellington, N.Z.) ; 40. 632.9510993 20 zbn96-124202 2 CONTENTS PART 1: DEVELOPMENT OF MULTI-SPECIES BAITING (D.R. Morgan, J. Innes, C. Ryan) Abstract 5 1. Introduction 5 2. Background 6 3. Objectives 6 4.
    [Show full text]
  • The Persistence and Secondary Poisoning Risks of Sodium Monofluoroacetate (1080), Brodifacoum, and Cholecalciferol in Possums
    THE PERSISTENCE AND SECONDARY POISONING RISKS OF SODIUM MONOFLUOROACETATE (1080), BRODIFACOUM, AND CHOLECALCIFEROL IN POSSUMS C. T. EASON, G. R. WRIGHT, and L. MEIKLE, Manaaki Whenua - Landcare Research, P.O. Box 69, Lincoln, New Zealand. P. ELDER, Steroid and Immunobiochemistry Unit, Christchurch Health Laboratories, Christchurch Hospital, P.O. Box 151, Christchurch, New Zealand. ABSTRACT: To determine the risk of secondary poisoning for animals preying on sub-lethally poisoned brushtail possums, captive possums were treated with near-lethal doses of sodium monofluoroacetate (1080) or brodifacoum, and toxicant concentrations in blood and tissue were monitored over time. Sodium monofluoroacetate was rapidly eliminated from the blood (within three days). Brodifacoum was retained in the liver and, to a lesser extent, the muscle of possums for eight months after dosing. To determine the potential risk for animals scavenging on the carcasses of possums poisoned with cholecalciferol, cats were fed poisoned carcasses for six days. No changes in behavior, appetite, or body weight were observed. Serum calcium concentrations increased slightly, but remained within the normal range for cats. KEY WORDS: vertebrate pest control, secondary poisoning, sodium monofluoroacetate, brodifacown, cholecalciferol Proc. 17th Yertebr. Pest Conf. (R.M. Timm & A.C. Crabb, Eds.) Published at Univ. of Calif., Davis. 1996. INTRODUCTION 1995), and toxic amounts of brodifacoum may be retained Sodium monofluoroacetate (1080) has been used for in a carcass. vertebrate pest control in New Zealand since 1954. It is The existence of an effective antidote to brodifacoum currently used most frequently in aerially sown baits and in the form of vitamin Kl means that dogs that have eaten in baits in bait stations for the control of the Australian carcasses containing brodifacoum residues can usually be brushtail possum (Trichosurus vulpecula) (Livingstone saved.
    [Show full text]
  • Occurrence, Elimination, and Risk of Anticoagulant Rodenticides in Wastewater and Sludge
    Occurrence, elimination, and risk of anticoagulant rodenticides in wastewater and sludge Silvia Lacorte, Cristian Gómez- Canela Department of Environmental Chemistry, IDAEA-CSIC, Jordi Girona 18-26, 08034 Barcelona Rats and super-rats Neverending story 1967 Coumachlor 1 tn rodenticides /city per campaign “It will be the LAST ONE” Rodenticides Biocides: use regulated according to EU. Used mainly as bait formulations. First generation: multiple feedings, less persistent in tissues, commensal and outdoor use. Second generation: single feeding (more toxic), more persistent in tissue, commensal use only. Toxic: vitamin K antagonists that cause mortality by blocking an animal’s ability to produce several key blood clotting factors. High oral, dermal and inhalation toxicity. Origin and fate of rodenticides Study site: Catalonia (7.5 M inhabitants) 1693 km of sewage corridor 13 fluvial tanks (70.000 m3) 130,000,000 € / 8 YEARS 32,000 km2 378,742 kg/y AI 2,077,000 € Objectives 1. To develop an analytical method to determine most widely used rodenticides in wastewater and sludge. 2. To monitor the presence of rodenticides within 9 WWTP receiving urban and agricultural waters. 3. To evaluate the risk of rodenticides using Daphnia magna as aquatic toxicological model. 4. To study the accumulation of rodenticides in sludge. Compounds studied Coumachlor* Pindone C19H15ClO4 C14H14O3 Dicoumarol Warfarin C19H12O6 C19H16O4 Coumatetralyl Ferulenol FGARs C19H16O3 C24H30O3 Acenocoumarol Chlorophacinone • Solubility C19H15NO6 C23H15ClO3 0.001-128 mg/L • pKa 3.4-6.6 Flocoumafen Bromadiolone C H F O C H BrO 33 25 3 40 30 23 4 • Log P 1.92-8.5 Brodifacoum Fluindione C H BrO 31 23 3 C15H9FO2 SGARs Difenacoum Fenindione C31H24O3 C15H10O2 1.
    [Show full text]
  • Wastewater-Borne Exposure of Limnic Fish to Anticoagulant Rodenticides
    Water Research 167 (2019) 115090 Contents lists available at ScienceDirect Water Research journal homepage: www.elsevier.com/locate/watres Wastewater-borne exposure of limnic fish to anticoagulant rodenticides * Julia Regnery a, , Pia Parrhysius a, Robert S. Schulz a, Christel Mohlenkamp€ a, Georgia Buchmeier b, Georg Reifferscheid a, Marvin Brinke a a Department of Biochemistry, Ecotoxicology, Federal Institute of Hydrology, Am Mainzer Tor 1, 56068 Koblenz, Germany b Unit Aquatic Ecotoxicology, Microbial Ecology, Bavarian Environment Agency, Demollstr. 31, 82407 Wielenbach, Germany article info abstract Article history: The recent emergence of second-generation anticoagulant rodenticides (AR) in the aquatic environment Received 18 June 2019 emphasizes the relevance and impact of aquatic exposure pathways during rodent control. Pest control Received in revised form in municipal sewer systems of urban and suburban areas is thought to be an important emission 12 September 2019 pathway for AR to reach wastewater and municipal wastewater treatment plants (WWTP), respectively. Accepted 13 September 2019 To circumstantiate that AR will enter streams via effluent discharges and bioaccumulate in aquatic or- Available online 14 September 2019 ganisms despite very low predicted environmental emissions, we conducted a retrospective biological monitoring of fish tissue samples from different WWTP fish monitoring ponds exclusively fed by Keywords: fl Bioaccumulation municipal ef uents in Bavaria, Germany. At the same time, information about rodent control in asso- Biocides ciated sewer systems was collected by telephone survey to assess relationships between sewer baiting Monitoring and rodenticide residues in fish. In addition, mussel and fish tissue samples from several Bavarian surface PBT-Substances waters with different effluent impact were analyzed to evaluate the prevalence of anticoagulants in Sewer baiting indigenous aquatic organisms.
    [Show full text]
  • Design for the Environment Toolkit: a Competitive Edge for the Future
    Design for the Environment A Competitive Edge for the Future Toolkit Design for Environment Toolkit(DfE) Minnesota Office of Environmental Assistance Minnesota Technical Assistance Program (MnTAP) Table of Contents vAbout the Authors...2 vAcknowledgments...3 vPreface...4 vPart One: Introduction to Design for the Environment (DfE)...6 What is DfE?...6 Why DfE?...10 Success in DfE...12 Implementing DfE...13 vPart Two: DfE Matrices and Questions...17 Explanation of the DfE Matrix System..17 Figure: Product DfE Matrix...18 Instructions For Using the DfE Matrix...19 Interpretation of Results...28 Matrix Questions...20 Definitions...30 vPart Three: Reference Information...32 Index of Hazardous Chemical Pollutants (alphabetical listing)...32 Plastics Environmental Risk Information...57 Figure: Recycling Rates and Commodity Price Information....58 Index of Climate Altering Chemicals...59 Polymers....61 Degradable Polymers - Vendor List...62 Part/Materials Suppliers Environmental Survey...65 Additional Resources...66 Works Cited....68 Summary of References...69 Other Vendor Lists Checklist of Printed Resources for Minnesota Businesses Outlets for Industrial Scrap Pallets Alternative Solvent Degreasers Manufacturers of Aqueous Cleaning Equipment Aqueous and Semi-Aqueous Cleaners for Metal Part Degreasing Safer Stripping and Cleaning Chemicals for Coatings and Polymers Page 1 About the Authors Jeremy M. Yarwood - Research Specialist, Minnesota Technical Assistance Program (MnTAP) Mr. Yarwood has previously worked with MnTAP advising Minnesota companies in developing environmentally responsible processes. He received his B.S. Civil (Environmental) Engineering summa cum laude from the University of Minnesota. Mr. Yarwood is currently a graduate fellow in the Department of Civil Engineering at the University of Minnesota and plans to obtain a M.S.
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • BROMADIOLONE 0,05G/Kg
    BROMADIOLONE 0,05g/kg Ratimor Wax blocks When the product is being used in public areas, the areas treated must be marked during the treatment Wax blocks period and a notice explaining the risk of primary or secondary poisoning by the anticoagulant as well Active substance: Bromadiolone 0.05 g/kg Rodenticide as indicating the first measures to be taken in case of poisoning must be made available alongside (CAS no.: 28772-56-7) the baits. When tamper resistant bait stations are used, they should be clearly marked to show that Contains the human aversive agent denatonium benzoate, Bitrex. 20 g they contain rodenticides and that they should not be disturbed.EFFECT: Bromadiolone prevents the Ready-for-use bait for the control of rats and mice indoors and outdoors (around formation of prothrombin in blood and this causes haemorrhage and the death of a rodent. The product buildings only) and in sewers. is effective soon after swallowing. The death of individual rodents does not influence the resistance to For use only as a rodenticide. baits among other rodents that are still alive. It is effective against rodents resistant to anticoagulant For professional use only. rodenticides of the first generation. PRECAUTIONS AND CONDITIONS FOR SAFE USE The Safety phrases: Keep locked up and out of the reach of children. Keep away from food, resistance status of the target population should be taken into account when considering the choice drink and animal feedingstuffs. When using do not eat, drink or smoke. Wear suitable gloves. of rodenticide to be used. Avoid all contact by mouth.
    [Show full text]
  • First Evidence of Anticoagulant Rodenticides in Fish in German
    Environmental Science and Pollution Research https://doi.org/10.1007/s11356-018-1385-8 ADVANCEMENTS IN CHEMICAL METHODS FOR ENVIRONMENTAL RESEARCH First evidence of anticoagulant rodenticides in fish and suspended particulate matter: spatial and temporal distribution in German freshwater aquatic systems Matthias Kotthoff1 & Heinz Rüdel2 & Heinrich Jürling1 & Kevin Severin1 & Stephan Hennecke1 & Anton Friesen3 & Jan Koschorreck3 Received: 27 September 2017 /Accepted: 24 January 2018 # The Author(s) 2018. This article is an open access publication Abstract Anticoagulant rodenticides (ARs) have been used for decades for rodent control worldwide. Research on the exposure of the environment and accumulation of these active substances in biota has been focused on terrestrial food webs, but few data are available on the impact of ARs on aquatic systems and water organisms. To fill this gap, we analyzed liver samples of bream (Abramis brama) and co-located suspended particulate matter (SPM) from the German Environmental Specimen Bank (ESB). An appropriate method was developed for the determination of eight different ARs, including first- and second-generation ARs, in fish liver and SPM. Applying this method to bream liver samples from 17 and 18 sampling locations of the years 2011 and 2015, respectively, five ARs were found at levels above limits of quantifications (LOQs, 0.2 to 2 μgkg−1). For 2015, brodifacoum was detected in 88% of the samples with a maximum concentration of 12.5 μgkg−1. Moreover, difenacoum, bromadiolone, difethialone, and flocoumafen were detected in some samples above LOQ. In contrast, no first generation AR was detected in the ESB samples. In SPM, only bromadiolone could be detected in 56% of the samples at levels up to 9.24 μgkg−1.A temporal trend analysis of bream liver from two sampling locations over a period of up to 23 years revealed a significant trend for brodifacoum at one of the sampling locations.
    [Show full text]
  • Pharmacokinetics of Anticoagulant Rodenticides in Target and Non-Target Organisms Katherine Horak U.S
    University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln USDA National Wildlife Research Center - Staff U.S. Department of Agriculture: Animal and Plant Publications Health Inspection Service 2018 Pharmacokinetics of Anticoagulant Rodenticides in Target and Non-target Organisms Katherine Horak U.S. Department of Agriculture, [email protected] Penny M. Fisher Landcare Research Brian M. Hopkins Landcare Research Follow this and additional works at: https://digitalcommons.unl.edu/icwdm_usdanwrc Part of the Life Sciences Commons Horak, Katherine; Fisher, Penny M.; and Hopkins, Brian M., "Pharmacokinetics of Anticoagulant Rodenticides in Target and Non- target Organisms" (2018). USDA National Wildlife Research Center - Staff Publications. 2091. https://digitalcommons.unl.edu/icwdm_usdanwrc/2091 This Article is brought to you for free and open access by the U.S. Department of Agriculture: Animal and Plant Health Inspection Service at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in USDA National Wildlife Research Center - Staff ubP lications by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. Chapter 4 Pharmacokinetics of Anticoagulant Rodenticides in Target and Non-target Organisms Katherine E. Horak, Penny M. Fisher, and Brian Hopkins 1 Introduction The concentration of a compound at the site of action is a determinant of its toxicity. This principle is affected by a variety of factors including the chemical properties of the compound (pKa, lipophilicity, molecular size), receptor binding affinity, route of exposure, and physiological properties of the organism. Many compounds have to undergo chemical changes, biotransformation, into more toxic or less toxic forms. Because of all of these variables, predicting toxic effects and performing risk assess- ments of compounds based solely on dose are less accurate than those that include data on absorption, distribution, metabolism (biotransformation), and excretion of the compound.
    [Show full text]
  • Systematic Review of Tranexamic Acid Adverse Reactions
    arm Ph ac f ov l o i a g n il r a n u c o e J Journal of Pharmacovigilance Calapai et al., J Pharmacovigilance 2015, 3:4 ISSN: 2329-6887 DOI: 10.4172/2329-6887.1000171 Review Open Access Systematic Review of Tranexamic Acid Adverse Reactions Gioacchino Calapai2*, Sebastiano Gangemi1, Carmen Mannucci2, Paola Lucia Minciullo1, Marco Casciaro1, Fabrizio Calapai3, Maria Righi4 and Michele Navarra5 1Operative Unit of Allergy and Clinical Immunology, Department of Clinical and Experimental Medicine, University of Messina, Italy 2Department of Clinical and Experimental Medicine, University of Messina, Italy 3Centro Studi Pharma.Ca, Messina, Italy 4Department of Biomedical Sciences and Morphological and Functional Images, University of Messina, Italy 5Department of Drug Sciences and Health Products, University of Messina, Italy *Corresponding author: Gioacchino Calapai, Department of Clinical and Experimental Medicine, University of Messina, Via Consolare Valeria 5, 98125 Messina, Italy, Tel: +39 090 2213646; Fax: +39 090 221; E-mail: [email protected] Received date: July 06, 2015; Accepted date: July 14, 2015; Published date: July 20, 2015 Copyright: © 2015 Calapai G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Background Tranexamic acid is a synthetic lysine derivate that exerts its antifibrinolytic effect by reversible blocking lysine binding sites on plasminogen preventing fibrin degradation. It is widely used for haemorrhage or risk of haemorrhage in increased fibrinolysis or fibrinogenolysis. Aim The aim of our work was to review the literature regarding the best evidence on tranexamic adverse reactions and to describe them according to the apparatus involved.
    [Show full text]
  • New Zealand Data Sheet 1
    New Zealand Data Sheet 1. PRODUCT NAME NAXEN® 250 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each NAXEN 250 mg tablet contains 250 mg of Naproxen For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM NAXEN 250 mg tablets are yellow, biconvex, round tablet of 11 mm diameter with one face engraved NX250 and having a bisecting score. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses. 4. CLINICAL PARTICULARS 4.1. Therapeutic indications NAXEN is indicated in adults for the relief of symptoms associated with rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendonitis and bursitis, acute gout and primary dysmenorrhoea. NAXEN is indicated in children for juvenile arthritis. 4.2. Dose and method of administration After assessing the risk/benefit ratio in each individual patient, the lowest effective dose for the shortest possible duration should be used (see Section 4.4). During long-term administration the dose of naproxen may be adjusted up or down depending on the clinical response of the patient. A lower daily dose may suffice for long-term administration. In patients who tolerate lower doses well, the dose may be increased to 1000 mg per day when a higher level of anti-inflammatory/analgesic 1 | P a g e activity is required. When treating patients with naproxen 1000 mg/day, the physician should observe sufficient increased clinical benefit to offset the potential increased risk. Dose Adults For rheumatoid arthritis, osteoarthritis and ankylosing spondylitis Initial therapy: The usual dose is 500-1000 mg per day taken in two doses at 12 hour intervals.
    [Show full text]
  • The Phytochemistry of Cherokee Aromatic Medicinal Plants
    medicines Review The Phytochemistry of Cherokee Aromatic Medicinal Plants William N. Setzer 1,2 1 Department of Chemistry, University of Alabama in Huntsville, Huntsville, AL 35899, USA; [email protected]; Tel.: +1-256-824-6519 2 Aromatic Plant Research Center, 230 N 1200 E, Suite 102, Lehi, UT 84043, USA Received: 25 October 2018; Accepted: 8 November 2018; Published: 12 November 2018 Abstract: Background: Native Americans have had a rich ethnobotanical heritage for treating diseases, ailments, and injuries. Cherokee traditional medicine has provided numerous aromatic and medicinal plants that not only were used by the Cherokee people, but were also adopted for use by European settlers in North America. Methods: The aim of this review was to examine the Cherokee ethnobotanical literature and the published phytochemical investigations on Cherokee medicinal plants and to correlate phytochemical constituents with traditional uses and biological activities. Results: Several Cherokee medicinal plants are still in use today as herbal medicines, including, for example, yarrow (Achillea millefolium), black cohosh (Cimicifuga racemosa), American ginseng (Panax quinquefolius), and blue skullcap (Scutellaria lateriflora). This review presents a summary of the traditional uses, phytochemical constituents, and biological activities of Cherokee aromatic and medicinal plants. Conclusions: The list is not complete, however, as there is still much work needed in phytochemical investigation and pharmacological evaluation of many traditional herbal medicines. Keywords: Cherokee; Native American; traditional herbal medicine; chemical constituents; pharmacology 1. Introduction Natural products have been an important source of medicinal agents throughout history and modern medicine continues to rely on traditional knowledge for treatment of human maladies [1]. Traditional medicines such as Traditional Chinese Medicine [2], Ayurvedic [3], and medicinal plants from Latin America [4] have proven to be rich resources of biologically active compounds and potential new drugs.
    [Show full text]